sKL protects CKD-associated cardiomyopathy by targeting GSL gangliosides, therefore providing a basis to examine the effect of GZ667161 on CKD-induced stress and dysfunction using a 5/6 nephrectomy mouse model. Here, CTSA is linked to cardiomyopathy.